Allena Pharmaceuticals nabs $53 mln Series C
Newton, Massachusetts-based Allena Pharmaceuticals, a biopharmaceutical company focused on treating metabolic and orphan diseases, has closed $53 million in Series C funding. Partner Fund Management led the round with participation from other investors that included Fidelity Management & Research Company, Wellington Management Company, Frazier Healthcare, HBM BioCapital and Pharmstandard International S.A.
9 December 2015•4 mins read
